A Pilot Study of EZN-2968, an Antisense Oligonucleotide Inhibitor of HIF-1alpha, in Adults With Advance Solid Tumors

Trial Profile

A Pilot Study of EZN-2968, an Antisense Oligonucleotide Inhibitor of HIF-1alpha, in Adults With Advance Solid Tumors

Discontinued
Phase of Trial: Phase I

Latest Information Update: 20 May 2017

At a glance

  • Drugs RG 6061 (Primary)
  • Indications Liver metastases; Solid tumours
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 01 Feb 2014 Status changed from completed to discontinued according to results published in the Cancer Chemotherapy and Pharmacology.
    • 01 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 12 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top